knowledge -WSS

knowledge

author：explore 2025-09-14 10:05:45 - browse：33693

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Health insurers' Q3 question: how much care are people getting?

WSS

IVG is promising — but it won’t replace IVF quite yet

Nobel honors Karikó and Weissman's enduring partnership

Washington mulls new rules to avert another Change Healthcare

Abortion pill Supreme Court ruling could impact entire drug industry

6 solutions to address cancer drug shortages and others

Readout LOUD podcast: mifepristone case, GLP

hotspot

knowledge

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

The Readout: Lenmeldy, GLP

Activists slam private health insurers over coverage restrictions

What we owe ALS patients — and why one company fell short

Affirmative action in medical school literally saved lives

Primary care physicians play key roles in Alzheimer's management

Sports medicine is finally prioritizing gender equality

Study points to new risk in gene therapy death of Terry Horgan

BioMarin wins approval for gene therapy to treat hemophilia A

2023 Nobel Prize in Medicine goes to Karikó and Weissman

leisure time

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Patient advocates debate FDA's accelerated approval process

FDA's naming rule on biosimilars has undermined competition

CRISPR base editing slashes cholesterol levels in monkeys

Nobel honors Karikó and Weissman's enduring partnership

hotspot

knowledge

hotspot

hotspot